Clinical Trial Update: A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors [Phase 2]

View source ↗

Summary

A Phase II study evaluated ramucirumab with a somatostatin analog in patients with advanced, progressive carcinoid tumors. The trial has completed and results w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Tumor

Drugs mentioned

• Ramucirumab (ramucirumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Carcinoid Tumors | Phase 2 | Status: COMPLETED | Results posted: 2024-03-05